- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05112757
Effective Conversion of Individuals at Risk
December 8, 2022 updated by: Philips Electronics Nederland B.V. acting through Philips CTO organization
This study aims to guide participants in recognizing their OSA (obstructive sleep apnea) and AFib (atrial fibrillation) symptoms, realizing what medical conditions can cause these symptoms (if any) and inform the participants on their possible diagnosis
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The primary objective is to analyze how many patients at risk of medical conditions will be converted to a health care professional by a smartphone application.
Historical data (number of patients at risk of OSA and/or AFib that seeked help for their condition in the past year) from institute will be used as a reference.
We will refer to this as the 'baseline conversion rate', reflecting the natural transition of patients in the general healthcare system.
Study Type
Interventional
Enrollment (Actual)
77
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Sandford Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- High risk of OSA and/or AFib, as defined by the risk algorithm developed by Sanford health
- 18 years or older, with sufficient English language skills
- Owning a smartphone with a relatively new operating system (iOS v. 14 (Iphone 6S or higher) or an Android device v.11<)
- Able to download and handle an app on a smartphone
- Willing and able to give informed consent
Exclusion criteria:
- Diagnosed with OSA and/or AFib
- Diagnosed health issues that are potentially life threatening or causing mental issues (stroke, Alzheimer's Disease, depression, etc.)
- Pregnancy/breast feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
Smartphone app use
|
Use of a smartphone application
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effective conversion
Time Frame: 6 months after consent
|
Number of patients that visited the Primary Care Physician
|
6 months after consent
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tim Weysen, MSc, Philips Healthcare
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 24, 2022
Primary Completion (Actual)
December 8, 2022
Study Completion (Actual)
December 8, 2022
Study Registration Dates
First Submitted
October 19, 2021
First Submitted That Met QC Criteria
November 4, 2021
First Posted (Actual)
November 9, 2021
Study Record Updates
Last Update Posted (Estimate)
December 12, 2022
Last Update Submitted That Met QC Criteria
December 8, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICBE-S-000283
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Medtronic Cardiac Ablation SolutionsRecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)Australia, United States, France, Belgium, Switzerland, Czechia
-
China National Center for Cardiovascular DiseasesRecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field AblationChina
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
CortexAblacon, Inc.Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Boston Scientific CorporationRecruitingAtrial Fibrillation (AF) | Persistant Atrial FibrillationUnited States, Spain, Belgium, France, Netherlands, Germany, Hong Kong
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Boston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationHong Kong, Czechia, Croatia, Taiwan
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Medtronic Cardiac Ablation SolutionsNot yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
-
University Medical Centre LjubljanaEnrolling by invitationPersistent Atrial Fibrillation | Persistent Atrial Fibrillation LongstandingSlovenia
Clinical Trials on Smartphone application use
-
Stanford UniversityCompletedDepressive Disorder | Depression | Depression, Postpartum | Anxiety | Telemedicine | Mental Health | Cognitive TherapyUnited States
-
Saglik Bilimleri UniversitesiThe Scientific and Technological Research Council of TurkeyCompleted
-
Jordan University of Science and TechnologyCompletedUrinary IncontinenceJordan
-
Kibi International UniversityCompleted
-
University Hospital, MontpellierCompleted
-
Gunma UniversityCompletedSubthreshold DepressionJapan
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMalignant Solid Neoplasm | Sarcoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Central Nervous System NeoplasmUnited States
-
Recovery Record ResearchStanford UniversityCompletedBulimia Nervosa | Eating Disorders | Binge Eating DisorderUnited States
-
University Hospital, BrestUnknownPhysical Activity | Pregnant | Mobile Health AppsFrance
-
Radboud University Medical CenterMassachusetts General Hospital; McGill University; Hoffmann-La Roche; University... and other collaboratorsRecruitingBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson Disease | Parkinsonian Disorders | Basal Ganglia Diseases | Synucleinopathies | Neurodegenerative Diseases | REM Sleep Behavior Disorder | Prodromal Stage | Cerebral DisorderNetherlands